Video Experimental Relacionado
Updated: Sep 10, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.1K
Las bajas concentraciones de factor VII activado recombinante normalizan los patrones de coagulación al revertir los
Yasser Khder1, Serge Côté2, Klaus Peter Hoffmann3
1Anthos Therapeutics, Cambridge, Massachusetts, USA.
Research and practice in thrombosis and haemostasis
|August 21, 2025
Resumen
Las dosis bajas de factor VIIa activado recombinante (rFVIIa) revertieron efectivamente los efectos anticoagulantes de abelacimab, un inhibidor de la FXI/ FXIa. Esto sugiere que rFVIIa puede controlar el sangrado en pacientes tratados con abelacimab.
Área de la Ciencia:
- Hematología
- Farmacología
Sus antecedentes:
- El factor VIIa activado recombinante (rFVIIa) se utiliza para el sangrado en la deficiencia de factor XI.
- Abelacimab es un inhibidor del Factor XI/XIa con propiedades anticoagulantes.
Objetivo del estudio:
- Evaluar si la dosis baja de rFVIIa puede contrarrestar los cambios de coagulación inducidos por abelacimab.
- Para evaluar la eficacia de rFVIIa se utilizará la tromboelastometría rotacional (ROTEM).
Principales métodos:
- La sangre entera de donantes sanos fue tratada con abelacimab.
- Adición posterior de rFVIIa o vehículo.
- Los parámetros de coagulación (tiempo de coagulación, tiempo de formación de coágulos, ángulo alfa) se midieron mediante ROTEM.
Principales resultados:
- Abelacimab prolongó significativamente el tiempo de coagulación y disminuyó el ángulo alfa.
- Las bajas concentraciones de rFVIIa (0, 5 - 1 μg/ ml) revirtieron estos efectos inducidos por abelacimab.
- Parámetros ROTEM normalizados con adición de rFVIIa.
Conclusiones:
- La dosis baja de rFVIIa corrige efectivamente el impacto de abelacimab en la coagulación.
- rFVIIa es una opción terapéutica potencial para el tratamiento de la hemorragia en pacientes tratados con abelacimab.
Palabras clave:
El proyecto ROTEMabelacimab tambiénAnticoagulantes y sus derivadosInhibidor del factor XIaFVIIa recombinanteMás Videos Relacionados
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
01:06Coagulation
374
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
374